{"efta_number": "EFTA01961023", "page_count": 4, "url": "https://epstein-data.com/EFTA01961023", "pdf_url": "https://epstein-data.com/pdf/EFTA01961023.pdf", "pages": [{"efta_number": "EFTA01961023", "page_number": 0, "text_content": "Financier, Jeffrey Epstein, Accelerates the Course of Evolution at Harvard\nEvolution is always on the move but nowhere has it been more in flux than at Harvard University.\nIndeed ten years ago, an Austrian biologist and mathematician called Martin Nowak, at the\nAdvanced Institute for Studies at Princeton, met with an unknown New York financier called\nJeffrey Epstein, to discuss the evolution of language. Epstein was by then an established\nphilanthropist in the sciences. But what emerged was far more pragmatic than the first\nevolutionary theory of irregular verbs. What emerged was an entire department at Harvard, under\nNowak's direction, to study the evolution of human diseases with the primary use of mathematics.\nThe department, called the Program for Evolutionary Dynamics or PED, was no ordinary\ndepartment. Epstein established it in August 2003, with an unprecedented $30 million dollar gift\nto the university. It quickly became one of the first of its kind to study the mathematical evolution\nof micro biology, notably cancer, infectious diseases and viruses such as HIV-in view of\nadvancing their treatment.\nAnd by creating the first mathematical models of how human cancer cells, viruses and bacteria\nevolve, Nowak and his graduate team have been able to identify groundbreaking aspects about\nthese diseases and steps to treat them more effectively.\nThe somewhat calculated meeting between the two men first occurred in March of 2000 when\nEpstein, with a passion for cutting-edge science, flew Nowak to his island in the US Virgin\nIslands to host a conference on the evolution of language. It was an obscure topic, but Epstein,\nfamiliar with Nowak's HIV work at Princeton, wanted to get to know the scientist intimately and\nif that involved furthering Nowak's current research on language, so be it.\nAt that time, Nowak was head of the Program in Theoretical Biology at the Institute for\nAdvanced Study at Princeton and had already published a substantial amount of work on the\nmathematics of the HIV virus, infectious bacteria, and cancer cells. Before going to Princeton,\nNowak had been the head of the mathematical-biology group at Oxford University. His\nmotivation for research differed from Epstein's. While they were both enraptured with unraveling\nthe big questions about existence, Nowak is a practicing Roman Catholic and a declared humanist\nwith a desire to serve society. Epstein on the other hand, is first and foremost a problem solver,\ninterested in strategy and intellectual puzzles. He is equally devoted to physics, artificial\nEFTA_R1_00435626\nEFTA01961023\n", "char_count": 2590}, {"efta_number": "EFTA01961023", "page_number": 1, "text_content": "intelligence, and the human brain. According to Nowak, Epstein was fascinated with his game\ntheory of win-stay, lose-shift and eager to see how it could be applied to the markets. That is not\nto say that Epstein had no interest in purely humanistic endeavors. He has given to countless\norganizations to further early and primary education, notably in the U.S. Virgin Islands, where his\nfoundation is based. But his essence is in uncovering the big questions, a possible but perhaps\ninsatiable desire.\nEpstein was not amateur philanthropist or science groupee. By 2003, he had supported the\nresearch of many prominent scientists, including Stephen Hawking, Marvin Minsky, Eric Lander,\nGeorge Church, and Nobel laureate physicists Gerard 't Hooft, David Gross, and Frank Wilczek.\nAccording to New York Magazine, he is one of the largest donors to individual scientists around\nthe world, granting up to $200 million a year. He was also a member of the New York Academy\nof Science, a member of Rockefeller University's board, and actively involved in the Santa Fe\nInstitute, the Quantum Gravity Program at the University of Pennsylvania, and the Mind, Brain &\nBehavior Advisory Committee at Harvard. Epstein himself had studied physics at the Cooper\nUnion in New York and mathematics at the Courant Institute in New York and moved on to\nteaching calculus and physics at the Dalton School in Manhattan. Within a couple of years, he was\nquickly recruited into options trading on Wall Street and applied his mathematical wit to the\nmarkets, focusing on the then popular Black Scholes model.\nBut Epstein's heart remained in the pure sciences. He was fascinated by fundamental questions on\nthe one hand, and as a fervent businessman, eager to apply scientific theory to the real world. It\nwas this combination that drew him to Nowak. For Nowak's work embodied both large\ntheoretical concepts about evolution and also focused on the treatment of disease with the use of\nevolutionary mathematics. Epstein could not only probe a brilliant mind about the origins of life,\nbut, with his connections at Harvard, was able to provide Nowak a powerful platform to put his\npioneering medical research into immediate practice.\nSo in August 2003, with the cooperation of Lawrence Summers, then president of Harvard, the\nProgram for Evolutionary Dynamics (PED) set up for business under the direction of Nowak,\nwho was made a professor of mathematics and biology at Harvard.\nPED's math models soon led to key discoveries towards combatting diseases of all kinds. In\n2012, Nowak and two postdoctoral students, Benjamin Allen and Ivana Bozic, developed the first\nEFTA_R1_00435627\nEFTA01961024\n", "char_count": 2669}, {"efta_number": "EFTA01961023", "page_number": 2, "text_content": "mathematical model of how human colon-cancer cells evolve and how they become immune to\ninhibitor-drug therapy. Their research was conducted at the request of the Pathology and\nOncology Department at Johns Hopkins University. The department was trying to understand\nhow the KRAS gene in colon-cancer cells becomes activated after inhibitor-drug therapy, making\nthe cells resistant to treatment.\nBy developing a mathematical model of the growth of colon-cancer cells, Nowak and his team\nshowed that the KRAS gene is not actually activated or \"switched on\" by inhibitor therapy;\nrather, a small percentage of colon-cancer cells with an already activated KRAS gene are immune\nfrom the start and come to dominate as the other cancer cells are destroyed by the inhibitor drug.\nThe discovery was critical in changing the approach to inhibitor-drug therapy. Instead of applying\ndrugs in sequence to fight secondary and tertiary resistance, the researchers at Johns Hopkins are\nnow exploring the effects of using a cocktail of inhibitor drugs to capture all colon-cancer cell\ntypes: those with the activated KRAS gene and those without. The same tailored approach is\nunderway for other cancers.\nIn 2010, Ivana Bozic and Martin Nowak co-authored a mathematical study that showed that most\nsolid tumors contain 40 to 100 genetic mutations, but that on average only 5 to 15 of those\nactually drive tumor growth. The findings were essential to the researchers at Johns Hopkins and\nelsewhere because they demonstrated the importance of isolating a key minority of mutated tumor\ncells for effective inhibitor treatment.\n\"Mathematics in medical research reveals patterns that are otherwise hidden,\" remarked Epstein,\nwho maintains a frequent presence at PED. \"It's exhilarating when a mathematician can determine\nmolecular and cellular behavior with the precision of an engineer and share those findings with\nphysicians.\"\nIn that same year 2010, the PED presented to Bert Vogelstein, professor and director of the\nLudwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Kimmel Cancer\nCenter and the Howard Hughes Medical Institute, a mathematical model showing the genetic\nevolution of pancreatic-cancer cells from initial mutation to non-primary malignant cells. What\nNowak's team had found was surprising: that pancreatic cancer, one of the most lethal forms of\ncancer, is not fast and furious as believed, but slow to develop. In fact, given the amount and type\nof genetic disparity between the cellular stages, it appears that it takes about ten years for an\nEFTA_R1_00435628\nEFTA01961025\n", "char_count": 2594}, {"efta_number": "EFTA01961023", "page_number": 3, "text_content": "initiating mutation to grow to a parental, non-metastatic founder cell and another six years for\ncells to become malignant.\nThe findings highlighted the importance and real possibility of isolating pancreatic mutations prior\nto metastasis. Johns Hopkins scientists are now focusing on developing a pancreatic cancer\nscreening method similar to the protocol used for breast and colon cancers. Though early stages\nof pancreatic cancer cause no known symptoms, the John Hopkins team is looking into pancreatic\nscreening endoscopies for patients of a certain age.\nOver the last two years, Nowak and his team have also collaborated with the Johns Hopkins to\ndevelop a database to map and predict the effect of drugs on the HIV virus. Like cancer cells,\nHIV often develops resistance to drug cocktails. This is a major problem for patients and the trial\nand error of clinical trials can be hugely debilitating. Using data collected from thousands of blood\ntests on more than 20 anti-HIV drugs, the model calculates each drug's ability to suppress viral\nreplication and avoid resistant HIV strains. The model also factors in different drug combinations\nand dosages, and information about the patient such as blood type, age, and sex to arrive at the\nmost precisely engineered predictor of results for future patients.\nMuch has been written about the Program for Evolutionary Dynamics and Nowak's work.\nNowak is also the honored recipient of numerous awards, a frequent guest lecturer and the author\nof several books. And while Jeffrey Epstein remains an obscure figure, tarnished now by a series\nof scandals involving underage women, one of which led to an 18-month jail sentence, he is\nnonetheless the talented catalyst, the accelerator of all this medical discovery. Whatever his\nignominy, Epstein's continued bond with Nowak and PED emphasizes that nature is neither\nfastidious nor judgmental, nor is its dynamic always gradual. Discovery can be sparked into being\nby an unlikely combustion, pragmatically driven and above all, errs towards sustainability, its\ngreat self, no matter how outlying its' gaze.\nEFTA_R1_00435629\nEFTA01961026\n", "char_count": 2133}]}